{
  "doc_id": "35",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "评中国成人2型糖尿病胰岛素促泌剂应用专家共识 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "评中国成人2型糖尿病胰岛素促泌剂应用专家共识 ",
          "start_idx": 0,
          "end_idx": 23,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T1",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 5,
              "end_idx": 7,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T2",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 16,
              "entity_en": "Insulin secretagogues"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R0",
              "head_entity_id": "T1",
              "tail_entity_id": "T0"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R1",
              "head_entity_id": "T2",
              "tail_entity_id": "T0"
            }
          ],
          "sentence_en": "Comments on the expert consensus on the use of insulin secretagogues in Chinese adults with type 2 diabetes"
        }
      ],
      "paragraph_en": "Comments on the expert consensus on the use of insulin secretagogues in Chinese adults with type 2 diabetes"
    },
    {
      "paragraph_id": "1",
      "paragraph": "胰岛素促泌剂是临床应用最早、最广泛的口服降糖药之一，降糖疗效肯定、安全性高、价格低廉、可与其他口服降糖药联用，在2型糖尿病(T2DM)治疗中占有重要地位，是多数国际权威人T2DM防治指南中的一线降糖药物。为了强调其重要性及正确认识和评价这一大类降糖药、中华医学会内分泌学分会于2011年讨论通过了《中国成人2型糖尿病胰岛素促泌剂应用的专家共识》，并于2012年正式表发。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "胰岛素促泌剂是临床应用最早、最广泛的口服降糖药之一，降糖疗效肯定、安全性高、价格低廉、可与其他口服降糖药联用，在2型糖尿病(T2DM)治疗中占有重要地位，是多数国际权威人T2DM防治指南中的一线降糖药物。为了强调其重要性及正确认识和评价这一大类降糖药、中华医学会内分泌学分会于2011年讨论通过了《中国成人2型糖尿病胰岛素促泌剂应用的专家共识》，并于2012年正式表发。",
          "start_idx": 0,
          "end_idx": 185,
          "entities": [
            {
              "entity_id": "T3",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T4",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "oral"
            },
            {
              "entity_id": "T5",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "oral"
            },
            {
              "entity_id": "T6",
              "entity": "2型糖尿病(T2DM)",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 67,
              "entity_en": "Type 2 diabetes mellitus (T2DM)"
            },
            {
              "entity_id": "T7",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 56,
              "end_idx": 58,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T8",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 85,
              "end_idx": 89,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T9",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 153,
              "end_idx": 158,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T10",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 153,
              "end_idx": 155,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T11",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 158,
              "end_idx": 164,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T12",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 85,
              "end_idx": 87,
              "entity_en": "T2"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R2",
              "head_entity_id": "T4",
              "tail_entity_id": "T3"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R3",
              "head_entity_id": "T7",
              "tail_entity_id": "T6"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R4",
              "head_entity_id": "T12",
              "tail_entity_id": "T8"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R5",
              "head_entity_id": "T10",
              "tail_entity_id": "T9"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R6",
              "head_entity_id": "T11",
              "tail_entity_id": "T9"
            }
          ],
          "sentence_en": "Insulin secretagogues are one of the earliest and most widely used oral hypoglycemic drugs in clinical practice. They have a positive hypoglycemic effect, high safety, low price, and can be used in combination with other oral hypoglycemic drugs. They play an important role in the treatment of type 2 diabetes mellitus (T2DM) and are the first-line hypoglycemic drugs in most international authoritative T2DM prevention and treatment guidelines. In order to emphasize its importance and correctly understand and evaluate this large category of hypoglycemic drugs, the Endocrinology Branch of the Chinese Medical Association discussed and passed the \"Expert Consensus on the Use of Insulin Secretagogues in Chinese Adults with Type 2 Diabetes\" in 2011, and officially published it in 2012."
        },
        {
          "sentence_id": "1",
          "sentence": " ",
          "start_idx": 185,
          "end_idx": 186,
          "entities": [],
          "relations": [],
          "sentence_en": " "
        }
      ],
      "paragraph_en": "Insulin secretagogues are one of the earliest and most widely used oral hypoglycemic drugs in clinical practice. They have a positive hypoglycemic effect, high safety, low price, and can be used in combination with other oral hypoglycemic drugs. They play an important role in the treatment of type 2 diabetes mellitus (T2DM) and are the first-line hypoglycemic drugs in most international authoritative T2DM prevention and treatment guidelines. In order to emphasize its importance and correctly understand and evaluate this large category of hypoglycemic drugs, the Endocrinology Branch of the Chinese Medical Association discussed and passed the \"Expert Consensus on the Use of Insulin Secretagogues in Chinese Adults with Type 2 Diabetes\" in 2011, and officially published it in 2012."
    },
    {
      "paragraph_id": "2",
      "paragraph": "1 胰岛素促泌剂的作用机制及特点 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1 胰岛素促泌剂的作用机制及特点 ",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [
            {
              "entity_id": "T13",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 8,
              "entity_en": "Insulin secretagogues"
            }
          ],
          "relations": [],
          "sentence_en": "1 Mechanism of action and characteristics of insulin secretagogues"
        }
      ],
      "paragraph_en": "1 Mechanism of action and characteristics of insulin secretagogues"
    },
    {
      "paragraph_id": "3",
      "paragraph": "目前国内使用的胰岛素促泌剂包括磺脲类和格列奈类。磺脲类促泌剂包括半衰期较短的短效促泌剂(如格列吡嗪和格列喹酮)和半衰期较长的中长效促泌剂(如普通剂型的格列美脲、格列苯脲和格列齐特，以及通过特殊的胃肠道治疗系统(GITS)技术实现控释的格列吡嗪控释片和采用以亲水性羟丙甲纤维素为基质的缓释技术格列齐特缓释片)。格列奈类半衰期较短，属短效促剂，包括瑞格列奈和那格列奈。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前国内使用的胰岛素促泌剂包括磺脲类和格列奈类。",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [
            {
              "entity_id": "T14",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 13,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T15",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T16",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 23,
              "entity_en": "Meglitinides"
            }
          ],
          "relations": [],
          "sentence_en": "The insulin secretagogues currently used in China include sulfonylureas and glinides."
        },
        {
          "sentence_id": "1",
          "sentence": "磺脲类促泌剂包括半衰期较短的短效促泌剂(如格列吡嗪和格列喹酮)和半衰期较长的中长效促泌剂(如普通剂型的格列美脲、格列苯脲和格列齐特，以及通过特殊的胃肠道治疗系统(GITS)技术实现控释的格列吡嗪控释片和采用以亲水性羟丙甲纤维素为基质的缓释技术格列齐特缓释片)。",
          "start_idx": 24,
          "end_idx": 154,
          "entities": [
            {
              "entity_id": "T17",
              "entity": "磺脲类促泌剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "Sulfonylurea secretagogues"
            },
            {
              "entity_id": "T18",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T19",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 30,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T20",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 55,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T21",
              "entity": "格列苯脲",
              "entity_type": "Drug",
              "start_idx": 56,
              "end_idx": 60,
              "entity_en": "Glibenclamide"
            },
            {
              "entity_id": "T22",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 61,
              "end_idx": 65,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T23",
              "entity": "格列吡嗪控释片",
              "entity_type": "Drug",
              "start_idx": 93,
              "end_idx": 100,
              "entity_en": "Glipizide Extended Release Tablets"
            },
            {
              "entity_id": "T24",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 128,
              "entity_en": "Gliclazide extended-release tablets"
            }
          ],
          "relations": [],
          "sentence_en": "Sulfonylurea secretagogues include short-acting secretagogues with a shorter half-life (such as glipizide and gliclazide) and medium- and long-acting secretagogues with a longer half-life (such as ordinary dosage forms of glimepiride, glibenclamide and gliclazide, as well as glipizide controlled-release tablets that achieve controlled release through a special gastrointestinal therapeutic system (GITS) technology and gliclazide sustained-release tablets that use a hydrophilic hydroxypropyl methylcellulose-based sustained-release technology)."
        },
        {
          "sentence_id": "2",
          "sentence": "格列奈类半衰期较短，属短效促剂，包括瑞格列奈和那格列奈。",
          "start_idx": 154,
          "end_idx": 182,
          "entities": [
            {
              "entity_id": "T25",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T26",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T27",
              "entity": "那格列奈",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "Nateglinide"
            }
          ],
          "relations": [],
          "sentence_en": "Meglitinides have a short half-life and are short-acting agonists, including repaglinide and nateglinide."
        },
        {
          "sentence_id": "3",
          "sentence": " ",
          "start_idx": 182,
          "end_idx": 183,
          "entities": [],
          "relations": [],
          "sentence_en": " "
        }
      ],
      "paragraph_en": "The insulin secretagogues currently used in China include sulfonylureas and glinides. Sulfonylurea secretagogues include short-acting secretagogues with a short half-life (such as glipizide and gliclazide) and medium- and long-acting secretagogues with a long half-life (such as ordinary dosage forms of glimepiride, glibenclamide and gliclazide, as well as glipizide controlled-release tablets that achieve controlled release through a special gastrointestinal therapeutic system (GITS) technology and gliclazide sustained-release tablets that use a hydrophilic hydroxypropyl methylcellulose-based sustained-release technology). Glinides have a short half-life and are short-acting secretagogues, including repaglinide and nateglinide."
    },
    {
      "paragraph_id": "4",
      "paragraph": "磺脲类促泌剂通过与β细胞膜三磷酸腺苷(ATP)敏感的钾通道(KATP)的磺脲类药物受体(SUR)结合，ATP/ADP比值升高，KATP通道关闭，细胞内的K+外流受阻，胞内K+升高、细胞膜去极化，触发L2型电压依赖的Ca2+通道开放，细胞外Ca2+内流增加，胞质内Ca2+浓度升高，从而刺激胰岛素分泌颗粒向细胞外分泌。KATP通道也存在于大脑、心肌和血管平滑肌等组织。不同组织的SUR存在差异，不同胰岛素促泌剂会与β细胞不同分子量的SUR受体结合，且亲和力和解离速度也各不相同，这些是其产生药效学差异的原因。格列本脲可作用于SUR1和SUR2A，而格列齐特仅作用于SUR1。格列本脲和格列美脲各自与SUR1不同亚单位特异性结合，格列美脲与SUR的亲和力更强、结合和解离速度也更快。格列本脲与两个SUR1位点相结合，不易与受体脱离，且作用时间相对较长。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类促泌剂通过与β细胞膜三磷酸腺苷(ATP)敏感的钾通道(KATP)的磺脲类药物受体(SUR)结合，ATP/ADP比值升高，KATP通道关闭，细胞内的K+外流受阻，胞内K+升高、细胞膜去极化，触发L2型电压依赖的Ca2+通道开放，细胞外Ca2+内流增加，胞质内Ca2+浓度升高，从而刺激胰岛素分泌颗粒向细胞外分泌。",
          "start_idx": 0,
          "end_idx": 158,
          "entities": [
            {
              "entity_id": "T28",
              "entity": "磺脲类促泌剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "Sulfonylurea secretagogues"
            }
          ],
          "relations": [],
          "sentence_en": "Sulfonylurea secretagogues bind to the sulfonylurea drug receptor (SUR) of the adenosine triphosphate (ATP)-sensitive potassium channel (KATP) of the β-cell membrane, increasing the ATP/ADP ratio, closing the KATP channel, blocking the outflow of K+ from the cell, increasing the intracellular K+ and depolarizing the cell membrane, triggering the opening of the L2 type voltage-dependent Ca2+ channel, increasing the influx of extracellular Ca2+, and increasing the intracytoplasmic Ca2+ concentration, thereby stimulating the secretion of insulin secretory granules to the extracellular space."
        },
        {
          "sentence_id": "1",
          "sentence": "KATP通道也存在于大脑、心肌和血管平滑肌等组织。",
          "start_idx": 158,
          "end_idx": 183,
          "entities": [],
          "relations": [],
          "sentence_en": "KATP channels are also present in tissues such as the brain, myocardium, and vascular smooth muscle."
        },
        {
          "sentence_id": "2",
          "sentence": "不同组织的SUR存在差异，不同胰岛素促泌剂会与β细胞不同分子量的SUR受体结合，且亲和力和解离速度也各不相同，这些是其产生药效学差异的原因。",
          "start_idx": 183,
          "end_idx": 253,
          "entities": [
            {
              "entity_id": "T29",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 21,
              "entity_en": "Insulin secretagogues"
            }
          ],
          "relations": [],
          "sentence_en": "There are differences in SUR in different tissues. Different insulin secretagogues will bind to SUR receptors of different molecular weights in β cells with different affinities and dissociation rates, which are the reasons for their pharmacodynamic differences."
        },
        {
          "sentence_id": "3",
          "sentence": "格列本脲可作用于SUR1和SUR2A，而格列齐特仅作用于SUR1。",
          "start_idx": 253,
          "end_idx": 286,
          "entities": [
            {
              "entity_id": "T30",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T31",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 24,
              "entity_en": "Gliclazide"
            }
          ],
          "relations": [],
          "sentence_en": "Glibenclamide can act on both SUR1 and SUR2A, while gliclazide only acts on SUR1."
        },
        {
          "sentence_id": "4",
          "sentence": "格列本脲和格列美脲各自与SUR1不同亚单位特异性结合，格列美脲与SUR的亲和力更强、结合和解离速度也更快。",
          "start_idx": 286,
          "end_idx": 339,
          "entities": [
            {
              "entity_id": "T32",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T33",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 9,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T34",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 31,
              "entity_en": "Glimepiride"
            }
          ],
          "relations": [],
          "sentence_en": "Glibenclamide and glimepiride each specifically bind to different subunits of SUR1. Glimepiride has a stronger affinity for SUR and a faster binding and dissociation rate."
        },
        {
          "sentence_id": "5",
          "sentence": "格列本脲与两个SUR1位点相结合，不易与受体脱离，且作用时间相对较长。",
          "start_idx": 339,
          "end_idx": 374,
          "entities": [
            {
              "entity_id": "T35",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Glyburide"
            }
          ],
          "relations": [],
          "sentence_en": "Glibenclamide binds to two SUR1 sites, is not easily detached from the receptor, and has a relatively long duration of action."
        }
      ],
      "paragraph_en": "Sulfonylurea secretagogues bind to the sulfonylurea drug receptor (SUR) of the adenosine triphosphate (ATP)-sensitive potassium channel (KATP) of the β-cell membrane, increasing the ATP/ADP ratio, closing the KATP channel, blocking the outflow of K+ from the cell, increasing the intracellular K+, depolarizing the cell membrane, triggering the opening of the L2-type voltage-dependent Ca2+ channel, increasing the influx of extracellular Ca2+, and increasing the concentration of intracytoplasmic Ca2+, thereby stimulating the secretion of insulin secretory granules to the extracellular space. KATP channels are also present in tissues such as the brain, myocardium, and vascular smooth muscle. There are differences in the SUR of different tissues. Different insulin secretagogues bind to SUR receptors of different molecular weights of β-cells, and their affinity and dissociation rates are also different. These are the reasons for their pharmacodynamic differences. Glibenclamide can act on SUR1 and SUR2A, while gliclazide only acts on SUR1. Glibenclamide and glimepiride each specifically bind to different subunits of SUR1. Glimepiride has a stronger affinity for SUR and a faster binding and dissociation rate. Glibenclamide binds to two SUR1 sites, is not easy to dissociate from the receptor, and has a relatively long action time."
    },
    {
      "paragraph_id": "5",
      "paragraph": "近年来，通过对β细胞的电压钳研究证实，磺脲类药物可不作用于KATP而直接加强Ca2+依赖的胰岛素分泌作用。通过葡萄糖钳夹技术研究发现，磺脲类药物可使人体外周葡萄糖利用增加10%~52%(平均29%)。但促泌剂改善胰岛素敏感性的作用主要继发于葡萄糖毒性作用的改善。不同的促泌剂对胰岛素敏感性的影响可能存在差异，如格列美脲在离体培养的脂肪细胞和肌肉组织中具有直接的拟胰岛素和胰岛素增敏作用。有研究表明，磺脲类促泌剂还可以通过其他机制降低血糖，其降低空腹血糖的作用与其抑制基础肝糖的生成密切相关。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "近年来，通过对β细胞的电压钳研究证实，磺脲类药物可不作用于KATP而直接加强Ca2+依赖的胰岛素分泌作用。",
          "start_idx": 0,
          "end_idx": 53,
          "entities": [
            {
              "entity_id": "T36",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 24,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "In recent years, voltage clamp studies on β cells have confirmed that sulfonylureas can directly enhance Ca2+-dependent insulin secretion without acting on KATP."
        },
        {
          "sentence_id": "1",
          "sentence": "通过葡萄糖钳夹技术研究发现，磺脲类药物可使人体外周葡萄糖利用增加10%~52%(平均29%)。",
          "start_idx": 53,
          "end_idx": 100,
          "entities": [
            {
              "entity_id": "T37",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 19,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "Studies using glucose clamp technology have shown that sulfonylureas can increase peripheral glucose utilization in the human body by 10% to 52% (average 29%)."
        },
        {
          "sentence_id": "2",
          "sentence": "但促泌剂改善胰岛素敏感性的作用主要继发于葡萄糖毒性作用的改善。",
          "start_idx": 100,
          "end_idx": 131,
          "entities": [],
          "relations": [],
          "sentence_en": "However, the effect of secretagogues in improving insulin sensitivity is mainly secondary to the improvement of glucose toxicity."
        },
        {
          "sentence_id": "3",
          "sentence": "不同的促泌剂对胰岛素敏感性的影响可能存在差异，如格列美脲在离体培养的脂肪细胞和肌肉组织中具有直接的拟胰岛素和胰岛素增敏作用。",
          "start_idx": 131,
          "end_idx": 193,
          "entities": [
            {
              "entity_id": "T38",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 28,
              "entity_en": "Glimepiride"
            }
          ],
          "relations": [],
          "sentence_en": "Different secretagogues may have different effects on insulin sensitivity. For example, glimepiride has direct insulin-mimetic and insulin-sensitizing effects in cultured adipocytes and muscle tissues."
        },
        {
          "sentence_id": "4",
          "sentence": "有研究表明，磺脲类促泌剂还可以通过其他机制降低血糖，其降低空腹血糖的作用与其抑制基础肝糖的生成密切相关。",
          "start_idx": 193,
          "end_idx": 245,
          "entities": [
            {
              "entity_id": "T39",
              "entity": "磺脲类促泌剂",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 12,
              "entity_en": "Sulfonylurea secretagogues"
            },
            {
              "entity_id": "T40",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T41",
              "entity": "空腹血糖",
              "entity_type": "Test_items",
              "start_idx": 29,
              "end_idx": 33,
              "entity_en": "Fasting blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "Studies have shown that sulfonylurea secretagogues can also lower blood sugar through other mechanisms, and their effect of lowering fasting blood sugar is closely related to their inhibition of basal glycogen production."
        },
        {
          "sentence_id": "5",
          "sentence": " ",
          "start_idx": 245,
          "end_idx": 246,
          "entities": [],
          "relations": [],
          "sentence_en": " "
        }
      ],
      "paragraph_en": "In recent years, voltage clamp studies on β cells have confirmed that sulfonylureas can directly enhance Ca2+-dependent insulin secretion without acting on KATP. Studies using glucose clamp technology have found that sulfonylureas can increase human peripheral glucose utilization by 10% to 52% (average 29%). However, the effect of secretagogues in improving insulin sensitivity is mainly secondary to the improvement of glucose toxicity. Different secretagogues may have different effects on insulin sensitivity. For example, glimepiride has direct insulin-mimetic and insulin-sensitizing effects in ex vivo cultured adipocytes and muscle tissue. Studies have shown that sulfonylurea secretagogues can also lower blood sugar through other mechanisms, and their effect in lowering fasting blood sugar is closely related to their inhibition of basal glycogen production."
    },
    {
      "paragraph_id": "6",
      "paragraph": "格列奈类药物也与胰岛β细胞膜SUR结合，与磺脲类药物相比，促胰岛素分泌作用起效快、作用持续时间短，有效降低餐后血糖，同时不增加胰岛素分泌总量，不加重β细胞负荷，低血糖的发生率低。胰岛素促泌剂降糖主要与对β细胞的作用有关，胰外作用不如对β细胞的作用重要。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "格列奈类药物也与胰岛β细胞膜SUR结合，与磺脲类药物相比，促胰岛素分泌作用起效快、作用持续时间短，有效降低餐后血糖，同时不增加胰岛素分泌总量，不加重β细胞负荷，低血糖的发生率低。",
          "start_idx": 0,
          "end_idx": 89,
          "entities": [
            {
              "entity_id": "T42",
              "entity": "格列奈类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T43",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 26,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T45",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T46",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 80,
              "end_idx": 83,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R7",
              "head_entity_id": "T46",
              "tail_entity_id": "T42"
            }
          ],
          "sentence_en": "Glinides also bind to the pancreatic β-cell membrane SUR. Compared with sulfonylureas, they have a faster onset of insulin secretion and a shorter duration of action, effectively lowering postprandial blood sugar while not increasing the total amount of insulin secretion, increasing the β-cell load, and reducing the incidence of hypoglycemia."
        },
        {
          "sentence_id": "1",
          "sentence": "胰岛素促泌剂降糖主要与对β细胞的作用有关，胰外作用不如对β细胞的作用重要。",
          "start_idx": 89,
          "end_idx": 126,
          "entities": [
            {
              "entity_id": "T44",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "Insulin secretagogues"
            }
          ],
          "relations": [],
          "sentence_en": "The glucose-lowering effect of insulin secretagogues is mainly related to the effect on β cells, and the extra-pancreatic effects are not as important as the effects on β cells."
        }
      ],
      "paragraph_en": "Glinides also bind to the pancreatic β cell membrane SUR. Compared with sulfonylureas, they promote insulin secretion quickly and for a shorter duration, effectively lowering postprandial blood sugar without increasing the total amount of insulin secretion or the β cell load, and reducing the incidence of hypoglycemia. The glucose-lowering effect of insulin secretagogues is mainly related to their effects on β cells, and their extrapancreatic effects are not as important as their effects on β cells."
    },
    {
      "paragraph_id": "7",
      "paragraph": "2 对胰岛素促泌剂认识的误区 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2 对胰岛素促泌剂认识的误区 ",
          "start_idx": 0,
          "end_idx": 15,
          "entities": [
            {
              "entity_id": "T47",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 9,
              "entity_en": "Insulin secretagogues"
            }
          ],
          "relations": [],
          "sentence_en": "2 Misunderstandings about insulin secretagogues"
        }
      ],
      "paragraph_en": "2 Misunderstandings about insulin secretagogues"
    },
    {
      "paragraph_id": "8",
      "paragraph": "2.1 低血糖风险高",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.1 低血糖风险高",
          "start_idx": 0,
          "end_idx": 10,
          "entities": [
            {
              "entity_id": "T48",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [],
          "sentence_en": "2.1 High risk of hypoglycemia"
        }
      ],
      "paragraph_en": "2.1 High risk of hypoglycemia"
    },
    {
      "paragraph_id": "9",
      "paragraph": "低血糖是磺脲类药物最常见的不良反度。但剂型改良后的格列吡嗪控释片、格列齐特缓释片和格列美脲等中长效制剂及餐时血糖调节药格列奈类，因其较低的血药浓度和依赖葡萄糖的降糖作用，低血糖的发生率低。GUIDE结果显示，在血糖水平控制相似的情况下，不同磺脲类促泌剂所致低血糖发生风险不同。糖尿病和心血管疾病行动研究(ADVANCE)以格列齐特缓释片为基瑞的降糖治疗严重低血糖年发生率仅为英国前瞻性糖尿病研究(UKPDS)采用格列本脲和氯磺丙脲为基碗的降糖治疗的1/4。英国一般实践研究数据库表明，磺脲类药物使用者年低血糖的发生半为1.8%，其中2.0%为年龄>65岁。在磺脲类药物中，格列苯脲的低血糖发生率最高，格列齐特和格列吡嗪的低血糖发生风险比格列苯脲低25%和40%。UKPDS对使用氯磺丙脲、格列苯脲和胰岛素的T2DM患者进行10年的随访表明，其年低血糖的发生率分别为11.0%、17.7%和36.5%。公认的低血糖发生少的甘精胰岛素的大型研究最新结果显示，甘精胰岛素低血糖发生的风险明显高于口服药。由此可见，胰岛素促泌剂肯定存在低血糖风险，但是胰岛素的低血糖风险更大。因此需要时一般情况下应优先选择胰岛素促泌剂而不是胰岛素。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "低血糖是磺脲类药物最常见的不良反度。但剂型改良后的格列吡嗪控释片、格列齐特缓释片和格列美脲等中长效制剂及餐时血糖调节药格列奈类，因其较低的血药浓度和依赖葡萄糖的降糖作用，低血糖的发生率低。GUIDE结果显示，在血糖水平控制相似的情况下，不同磺脲类促泌剂所致低血糖发生风险不同。糖尿病和心血管疾病行动研究(ADVANCE)以格列齐特缓释片为基瑞的降糖治疗严重低血糖年发生率仅为英国前瞻性糖尿病研究(UKPDS)采用格列本脲和氯磺丙脲为基碗的降糖治疗的1/4。英国一般实践研究数据库表明，磺脲类药物使用者年低血糖的发生半为1.8%，其中2.0%为年龄>65岁。在磺脲类药物中，格列苯脲的低血糖发生率最高，格列齐特和格列吡嗪的低血糖发生风险比格列苯脲低25%和40%。UKPDS对使用氯磺丙脲、格列苯脲和胰岛素的T2DM患者进行10年的随访表明，其年低血糖的发生率分别为11.0%、17.7%和36.5%。",
          "start_idx": 0,
          "end_idx": 400,
          "entities": [
            {
              "entity_id": "T49",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T50",
              "entity": "格列吡嗪控释片",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 32,
              "entity_en": "Glipizide Extended Release Tablets"
            },
            {
              "entity_id": "T51",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 40,
              "entity_en": "Gliclazide extended-release tablets"
            },
            {
              "entity_id": "T52",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 41,
              "end_idx": 45,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T53",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 63,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T54",
              "entity": "磺脲类促泌剂",
              "entity_type": "Drug",
              "start_idx": 120,
              "end_idx": 126,
              "entity_en": "Sulfonylurea secretagogues"
            },
            {
              "entity_id": "T55",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 161,
              "end_idx": 168,
              "entity_en": "Gliclazide extended-release tablets"
            },
            {
              "entity_id": "T56",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 206,
              "end_idx": 210,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T57",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 211,
              "end_idx": 215,
              "entity_en": "Chlorpropamide"
            },
            {
              "entity_id": "T58",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 242,
              "end_idx": 247,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T59",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 279,
              "end_idx": 284,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T60",
              "entity": "格列苯脲",
              "entity_type": "Drug",
              "start_idx": 286,
              "end_idx": 290,
              "entity_en": "Glibenclamide"
            },
            {
              "entity_id": "T61",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 300,
              "end_idx": 304,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T62",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 305,
              "end_idx": 309,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T63",
              "entity": "格列苯脲",
              "entity_type": "Drug",
              "start_idx": 318,
              "end_idx": 322,
              "entity_en": "Glibenclamide"
            },
            {
              "entity_id": "T64",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 339,
              "end_idx": 343,
              "entity_en": "Chlorpropamide"
            },
            {
              "entity_id": "T65",
              "entity": "格列苯脲",
              "entity_type": "Drug",
              "start_idx": 344,
              "end_idx": 348,
              "entity_en": "Glibenclamide"
            },
            {
              "entity_id": "T66",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 349,
              "end_idx": 352,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T73",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T74",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 85,
              "end_idx": 88,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T75",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 128,
              "end_idx": 131,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T76",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 178,
              "end_idx": 181,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T77",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 251,
              "end_idx": 254,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T78",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 291,
              "end_idx": 294,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T79",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 310,
              "end_idx": 313,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T80",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 372,
              "end_idx": 375,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T85",
              "entity": "血药浓度",
              "entity_type": "Pathogenesis",
              "start_idx": 69,
              "end_idx": 73,
              "entity_en": "Blood concentration"
            },
            {
              "entity_id": "T86",
              "entity": "餐时血糖",
              "entity_type": "Test_items",
              "start_idx": 52,
              "end_idx": 56,
              "entity_en": "Mealtime blood sugar"
            },
            {
              "entity_id": "T87",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 105,
              "end_idx": 107,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T88",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 138,
              "end_idx": 141,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T89",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 142,
              "end_idx": 147,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T90",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 142,
              "end_idx": 145,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T91",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 192,
              "end_idx": 195,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T92",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 353,
              "end_idx": 357,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T93",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 353,
              "end_idx": 355,
              "entity_en": "T2"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R8",
              "head_entity_id": "T73",
              "tail_entity_id": "T49"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R9",
              "head_entity_id": "T74",
              "tail_entity_id": "T50"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R10",
              "head_entity_id": "T74",
              "tail_entity_id": "T51"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R11",
              "head_entity_id": "T74",
              "tail_entity_id": "T52"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R12",
              "head_entity_id": "T74",
              "tail_entity_id": "T53"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R13",
              "head_entity_id": "T75",
              "tail_entity_id": "T54"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R14",
              "head_entity_id": "T76",
              "tail_entity_id": "T55"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R15",
              "head_entity_id": "T55",
              "tail_entity_id": "T88"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R16",
              "head_entity_id": "T76",
              "tail_entity_id": "T56"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R17",
              "head_entity_id": "T56",
              "tail_entity_id": "T91"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R18",
              "head_entity_id": "T76",
              "tail_entity_id": "T57"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R19",
              "head_entity_id": "T57",
              "tail_entity_id": "T91"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R20",
              "head_entity_id": "T77",
              "tail_entity_id": "T58"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R21",
              "head_entity_id": "T78",
              "tail_entity_id": "T60"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R22",
              "head_entity_id": "T79",
              "tail_entity_id": "T61"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R23",
              "head_entity_id": "T79",
              "tail_entity_id": "T62"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R24",
              "head_entity_id": "T79",
              "tail_entity_id": "T63"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R25",
              "head_entity_id": "T80",
              "tail_entity_id": "T64"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R26",
              "head_entity_id": "T64",
              "tail_entity_id": "T92"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R27",
              "head_entity_id": "T80",
              "tail_entity_id": "T65"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R28",
              "head_entity_id": "T65",
              "tail_entity_id": "T92"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R29",
              "head_entity_id": "T80",
              "tail_entity_id": "T66"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R30",
              "head_entity_id": "T66",
              "tail_entity_id": "T92"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R35",
              "head_entity_id": "T90",
              "tail_entity_id": "T89"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R36",
              "head_entity_id": "T93",
              "tail_entity_id": "T92"
            }
          ],
          "sentence_en": "Hypoglycemia is the most common adverse reaction of sulfonylureas. However, the incidence of hypoglycemia is low in glipizide controlled-release tablets, gliclazide extended-release tablets, glimepiride and other medium- and long-acting preparations and mealtime blood sugar regulating drugs such as glinides due to their lower blood concentration and glucose-dependent hypoglycemic effect. GUIDE results show that the risk of hypoglycemia caused by different sulfonylurea secretagogues is different when blood sugar levels are controlled at similar levels. The annual incidence of severe hypoglycemia in the diabetes and cardiovascular disease action study (ADVANCE) based on gliclazide extended-release tablets was only 1/4 of that in the UK Prospective Diabetes Study (UKPDS) based on glibenclamide and chlorpropamide. The UK General Practice Research Database shows that the annual incidence of hypoglycemia in sulfonylurea users is 1.8%, of which 2.0% are aged >65 years. Among sulfonylureas, glibenclamide has the highest incidence of hypoglycemia, while the risk of hypoglycemia with gliclazide and glipizide is 25% and 40% lower than that with glibenclamide. A 10-year follow-up of T2DM patients using chlorpropamide, glibenclamide, and insulin by UKPDS showed that the annual incidence of hypoglycemia was 11.0%, 17.7%, and 36.5%, respectively."
        },
        {
          "sentence_id": "1",
          "sentence": "公认的低血糖发生少的甘精胰岛素的大型研究最新结果显示，甘精胰岛素低血糖发生的风险明显高于口服药。",
          "start_idx": 400,
          "end_idx": 448,
          "entities": [
            {
              "entity_id": "T67",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Insulin glargine"
            },
            {
              "entity_id": "T68",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 32,
              "entity_en": "Insulin glargine"
            },
            {
              "entity_id": "T81",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T82",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 32,
              "end_idx": 35,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T94",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 44,
              "end_idx": 46,
              "entity_en": "oral"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R31",
              "head_entity_id": "T81",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R32",
              "head_entity_id": "T82",
              "tail_entity_id": "T68"
            }
          ],
          "sentence_en": "The latest results of a large-scale study on glargine insulin, which is recognized to have a low incidence of hypoglycemia, show that the risk of hypoglycemia with glargine insulin is significantly higher than that with oral medications."
        },
        {
          "sentence_id": "2",
          "sentence": "由此可见，胰岛素促泌剂肯定存在低血糖风险，但是胰岛素的低血糖风险更大。",
          "start_idx": 448,
          "end_idx": 483,
          "entities": [
            {
              "entity_id": "T69",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 11,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T70",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T83",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T84",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R33",
              "head_entity_id": "T83",
              "tail_entity_id": "T69"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R34",
              "head_entity_id": "T84",
              "tail_entity_id": "T70"
            }
          ],
          "sentence_en": "It can be seen from this that insulin secretagogues definitely have a risk of hypoglycemia, but the risk of hypoglycemia with insulin is greater."
        },
        {
          "sentence_id": "3",
          "sentence": "因此需要时一般情况下应优先选择胰岛素促泌剂而不是胰岛素。",
          "start_idx": 483,
          "end_idx": 511,
          "entities": [
            {
              "entity_id": "T71",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 21,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T72",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 27,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "Therefore, insulin secretagogues should generally be preferred over insulin when needed."
        },
        {
          "sentence_id": "4",
          "sentence": " ",
          "start_idx": 511,
          "end_idx": 512,
          "entities": [],
          "relations": [],
          "sentence_en": " "
        }
      ],
      "paragraph_en": "Hypoglycemia is the most common adverse reaction of sulfonylureas. However, the incidence of hypoglycemia is low in glipizide controlled-release tablets, gliclazide extended-release tablets, glimepiride and other medium- and long-acting preparations and mealtime blood sugar regulating drugs such as glinides due to their lower blood concentration and glucose-dependent hypoglycemic effect. GUIDE results show that the risk of hypoglycemia caused by different sulfonylurea secretagogues is different when blood sugar levels are controlled at similar levels. The annual incidence of severe hypoglycemia in the diabetes and cardiovascular disease action study (ADVANCE) based on gliclazide extended-release tablets was only 1/4 of that in the UK Prospective Diabetes Study (UKPDS) based on glibenclamide and chlorpropamide. The UK General Practice Research Database shows that the annual incidence of hypoglycemia in sulfonylurea users is 1.8%, of which 2.0% are aged >65 years. Among sulfonylureas, glibenclamide has the highest incidence of hypoglycemia, while the risk of hypoglycemia with gliclazide and glipizide is 25% and 40% lower than that with glibenclamide. A 10-year follow-up of T2DM patients using chlorpropamide, glibenclamide and insulin by UKPDS showed that the annual incidence of hypoglycemia was 11.0%, 17.7% and 36.5%, respectively. The latest results of a large-scale study of glargine insulin, which is recognized to have a low incidence of hypoglycemia, showed that the risk of hypoglycemia with glargine insulin is significantly higher than that with oral medications. This shows that insulin secretagogues definitely have a risk of hypoglycemia, but the risk of hypoglycemia with insulin is greater. Therefore, when necessary, insulin secretagogues should generally be preferred over insulin."
    },
    {
      "paragraph_id": "10",
      "paragraph": "2.2 体重增加明显 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.2 体重增加明显 ",
          "start_idx": 0,
          "end_idx": 11,
          "entities": [
            {
              "entity_id": "T95",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 4,
              "end_idx": 8,
              "entity_en": "Weight gain"
            }
          ],
          "relations": [],
          "sentence_en": "2.2 Significant weight gain"
        }
      ],
      "paragraph_en": "2.2 Significant weight gain"
    },
    {
      "paragraph_id": "11",
      "paragraph": "目前一般认为磺脲类药物治疗可引起患者体重增加。UKPDS表明，以格列本脲为基础的降糖治疗，患者体重增加1.7kg。Schernthaner等对使用格列齐特和格列美脲治疗的患者行27周的随访发现，其体重增加分别为0.5kg和0.6kg。而ADVANCE5年的观察分析并未发现以格列齐特缓释片为基础的降糖治疗增加患者体重。很多大型研究表明胰岛素增加体重更明显，比如ADVANCE新近的分析发现用胰岛素体重增加3.3kg，而磺脲服类为0.7kg。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前一般认为磺脲类药物治疗可引起患者体重增加。UKPDS表明，以格列本脲为基础的降糖治疗，患者体重增加1.7kg。Schernthaner等对使用格列齐特和格列美脲治疗的患者行27周的随访发现，其体重增加分别为0.5kg和0.6kg。",
          "start_idx": 0,
          "end_idx": 117,
          "entities": [
            {
              "entity_id": "T96",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 11,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T97",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 36,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T98",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 73,
              "end_idx": 77,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T99",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 78,
              "end_idx": 82,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T102",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T103",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T104",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 98,
              "end_idx": 102,
              "entity_en": "Weight gain"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R37",
              "head_entity_id": "T102",
              "tail_entity_id": "T96"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R38",
              "head_entity_id": "T103",
              "tail_entity_id": "T97"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R39",
              "head_entity_id": "T104",
              "tail_entity_id": "T98"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R40",
              "head_entity_id": "T104",
              "tail_entity_id": "T99"
            }
          ],
          "sentence_en": "It is generally believed that sulfonylurea treatment can cause weight gain in patients. UKPDS shows that patients gain 1.7 kg of weight with glibenclamide-based hypoglycemic treatment. Schernthaner et al. followed up patients treated with gliclazide and glimepiride for 27 weeks and found that their weight gain was 0.5 kg and 0.6 kg, respectively."
        },
        {
          "sentence_id": "1",
          "sentence": "而ADVANCE5年的观察分析并未发现以格列齐特缓释片为基础的降糖治疗增加患者体重。",
          "start_idx": 117,
          "end_idx": 159,
          "entities": [
            {
              "entity_id": "T100",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 27,
              "entity_en": "Gliclazide extended-release tablets"
            }
          ],
          "relations": [],
          "sentence_en": "However, the 5-year observational analysis of ADVANCE did not find that glucose-lowering treatment based on gliclazide extended-release tablets increased patients' weight."
        },
        {
          "sentence_id": "2",
          "sentence": "很多大型研究表明胰岛素增加体重更明显，比如ADVANCE新近的分析发现用胰岛素体重增加3.3kg，而磺脲服类为0.7kg。",
          "start_idx": 159,
          "end_idx": 220,
          "entities": [
            {
              "entity_id": "T101",
              "entity": "磺脲服类",
              "entity_type": "Drug",
              "start_idx": 50,
              "end_idx": 54,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T105",
              "entity": "增加体重",
              "entity_type": "ADE",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Gaining weight"
            },
            {
              "entity_id": "T106",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 39,
              "end_idx": 43,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T107",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 11,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T108",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R41",
              "head_entity_id": "T105",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R42",
              "head_entity_id": "T106",
              "tail_entity_id": "T108"
            }
          ],
          "sentence_en": "Many large studies have shown that insulin causes a more significant increase in weight. For example, a recent analysis of ADVANCE found that insulin resulted in a 3.3kg increase in weight, while sulfonylureas resulted in a 0.7kg increase."
        }
      ],
      "paragraph_en": "It is generally believed that sulfonylurea treatment can cause weight gain in patients. UKPDS shows that patients gain 1.7kg in weight with glibenclamide-based hypoglycemic treatment. Schernthaner et al. followed up patients treated with gliclazide and glimepiride for 27 weeks and found that their weight gain was 0.5kg and 0.6kg, respectively. However, the 5-year observation and analysis of ADVANCE did not find that hypoglycemic treatment based on gliclazide sustained-release tablets increased patient weight. Many large studies have shown that insulin increases weight more significantly. For example, a recent analysis of ADVANCE found that insulin increased weight by 3.3kg, while sulfonylureas increased weight by 0.7kg."
    },
    {
      "paragraph_id": "12",
      "paragraph": "不难看出，胰岛素促泌剂增加体重，但胰岛素体重增加更明显。表明超重和肥胖的糖尿病患者选用降药时一般也应是胰岛素促泌剂优于胰岛素。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "不难看出，胰岛素促泌剂增加体重，但胰岛素体重增加更明显。表明超重和肥胖的糖尿病患者选用降药时一般也应是胰岛素促泌剂优于胰岛素。",
          "start_idx": 0,
          "end_idx": 63,
          "entities": [
            {
              "entity_id": "T109",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 11,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T110",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 20,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T111",
              "entity": "超重",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 32,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T112",
              "entity": "肥胖",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 35,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T113",
              "entity": "糖尿病",
              "entity_type": "Drug",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T114",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 57,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T115",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 62,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T116",
              "entity": "增加体重",
              "entity_type": "ADE",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Gaining weight"
            },
            {
              "entity_id": "T117",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 20,
              "end_idx": 24,
              "entity_en": "Weight gain"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R43",
              "head_entity_id": "T116",
              "tail_entity_id": "T109"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R44",
              "head_entity_id": "T117",
              "tail_entity_id": "T110"
            }
          ],
          "sentence_en": "It is not difficult to see that insulin secretagogues increase body weight, but insulin increases weight more significantly. This indicates that overweight and obese diabetic patients should generally choose insulin secretagogues over insulin when choosing weight-reducing drugs."
        },
        {
          "sentence_id": "1",
          "sentence": " ",
          "start_idx": 63,
          "end_idx": 64,
          "entities": [],
          "relations": [],
          "sentence_en": " "
        }
      ],
      "paragraph_en": "It is not difficult to see that insulin secretagogues increase body weight, but insulin increases weight more significantly. This indicates that overweight and obese diabetic patients should generally choose insulin secretagogues over insulin when choosing weight-reducing drugs."
    },
    {
      "paragraph_id": "13",
      "paragraph": "2.3加重β细胞功能衰竭",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.3加重β细胞功能衰竭",
          "start_idx": 0,
          "end_idx": 12,
          "entities": [
            {
              "entity_id": "T118",
              "entity": "β细胞功能衰竭",
              "entity_type": "Pathogenesis",
              "start_idx": 5,
              "end_idx": 12,
              "entity_en": "β-cell failure"
            }
          ],
          "relations": [],
          "sentence_en": "2.3 Aggravation of β-cell failure"
        }
      ],
      "paragraph_en": "2.3 Aggravation of β-cell failure"
    },
    {
      "paragraph_id": "14",
      "paragraph": "有研究认为胰岛素促泌剂可以引起胰岛β细胞凋亡，且促凋亡作用呈时间-剂量依赖性增加。UKPDS的结果显示，无论使用何种降糖治疗，胰岛β细胞功能每年以约7%的速度丧失，使用格列本脲和氯磺丙脲治疗的患者β细胞胰岛素分泌功能有下降趋势，但与采用二甲双胍治疗和单纯饮食控制相似。糖尿病进展试验(ADOPT)对比了3种不同类型降糖药物(罗格列酮、格列本脲和二甲双胍)在新诊断T2DM患者中的疗效，发现格列本脲改善β细胞胰岛素分泌功能明显优于罗格列酮和二甲双胍，并非发现磺脲类药物加重或加速了β细胞的衰竭。迄今的循证医学证据没有发现映岛素促泌剂加重或加速β细胞衰竭。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "有研究认为胰岛素促泌剂可以引起胰岛β细胞凋亡，且促凋亡作用呈时间-剂量依赖性增加。UKPDS的结果显示，无论使用何种降糖治疗，胰岛β细胞功能每年以约7%的速度丧失，使用格列本脲和氯磺丙脲治疗的患者β细胞胰岛素分泌功能有下降趋势，但与采用二甲双胍治疗和单纯饮食控制相似。糖尿病进展试验(ADOPT)对比了3种不同类型降糖药物(罗格列酮、格列本脲和二甲双胍)在新诊断T2DM患者中的疗效，发现格列本脲改善β细胞胰岛素分泌功能明显优于罗格列酮和二甲双胍，并非发现磺脲类药物加重或加速了β细胞的衰竭。",
          "start_idx": 0,
          "end_idx": 246,
          "entities": [
            {
              "entity_id": "T119",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 11,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T120",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 88,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T121",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 89,
              "end_idx": 93,
              "entity_en": "Chlorpropamide"
            },
            {
              "entity_id": "T122",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 118,
              "end_idx": 122,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T123",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 162,
              "end_idx": 166,
              "entity_en": "Rosiglitazone"
            },
            {
              "entity_id": "T124",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 167,
              "end_idx": 171,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T125",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 172,
              "end_idx": 176,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T126",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 194,
              "end_idx": 198,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T127",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 214,
              "end_idx": 218,
              "entity_en": "Rosiglitazone"
            },
            {
              "entity_id": "T128",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 219,
              "end_idx": 223,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T129",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 228,
              "end_idx": 233,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T131",
              "entity": "胰岛β细胞凋亡",
              "entity_type": "Pathogenesis",
              "start_idx": 15,
              "end_idx": 22,
              "entity_en": "Pancreatic β-cell apoptosis"
            },
            {
              "entity_id": "T132",
              "entity": "β细胞的衰竭",
              "entity_type": "Pathogenesis",
              "start_idx": 239,
              "end_idx": 245,
              "entity_en": "β-cell failure"
            },
            {
              "entity_id": "T134",
              "entity": "单纯饮食控制",
              "entity_type": "Treatment",
              "start_idx": 125,
              "end_idx": 131,
              "entity_en": "Simple diet control"
            },
            {
              "entity_id": "T135",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 134,
              "end_idx": 137,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T136",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 181,
              "end_idx": 185,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T137",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 181,
              "end_idx": 183,
              "entity_en": "T2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R45",
              "head_entity_id": "T123",
              "tail_entity_id": "T135"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R46",
              "head_entity_id": "T124",
              "tail_entity_id": "T135"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R47",
              "head_entity_id": "T125",
              "tail_entity_id": "T135"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R48",
              "head_entity_id": "T137",
              "tail_entity_id": "T136"
            }
          ],
          "sentence_en": "Some studies have shown that insulin secretagogues can cause pancreatic β-cell apoptosis, and the pro-apoptotic effect increases in a time-dose-dependent manner. The results of UKPDS showed that regardless of the type of hypoglycemic treatment used, pancreatic β-cell function was lost at a rate of about 7% per year. The β-cell insulin secretion function of patients treated with glibenclamide and chlorpropamide showed a downward trend, but was similar to that of metformin treatment and simple diet control. The Advanced Diabetes Progression Trial (ADOPT) compared the efficacy of three different types of hypoglycemic drugs (rosiglitazone, glibenclamide, and metformin) in newly diagnosed T2DM patients and found that glibenclamide was significantly better than rosiglitazone and metformin in improving β-cell insulin secretion function, but did not find that sulfonylurea drugs aggravated or accelerated β-cell failure."
        },
        {
          "sentence_id": "1",
          "sentence": "迄今的循证医学证据没有发现映岛素促泌剂加重或加速β细胞衰竭。",
          "start_idx": 246,
          "end_idx": 276,
          "entities": [
            {
              "entity_id": "T130",
              "entity": "映岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 19,
              "entity_en": "Insulin secretagogue"
            },
            {
              "entity_id": "T133",
              "entity": "β细胞衰竭",
              "entity_type": "Pathogenesis",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "Beta cell failure"
            }
          ],
          "relations": [],
          "sentence_en": "Evidence-based medicine to date has not found that insulin secretagogues aggravate or accelerate β-cell failure."
        },
        {
          "sentence_id": "2",
          "sentence": " ",
          "start_idx": 276,
          "end_idx": 277,
          "entities": [],
          "relations": [],
          "sentence_en": " "
        }
      ],
      "paragraph_en": "Some studies have shown that insulin secretagogues can cause pancreatic β-cell apoptosis, and the pro-apoptotic effect increases in a time-dose-dependent manner. The results of UKPDS showed that regardless of the type of hypoglycemic treatment used, pancreatic β-cell function was lost at a rate of about 7% per year. The β-cell insulin secretion function of patients treated with glibenclamide and chlorpropamide showed a downward trend, but was similar to that of metformin treatment and simple diet control. The Diabetes Progression Trial (ADOPT) compared the efficacy of three different types of hypoglycemic drugs (rosiglitazone, glibenclamide, and metformin) in newly diagnosed T2DM patients and found that glibenclamide was significantly better than rosiglitazone and metformin in improving β-cell insulin secretion function, but did not find that sulfonylurea drugs aggravated or accelerated β-cell failure. Evidence-based medicine to date has not found that insulin secretagogues aggravate or accelerate β-cell failure."
    },
    {
      "paragraph_id": "15",
      "paragraph": "2.4 心血管风险 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.4 心血管风险 ",
          "start_idx": 0,
          "end_idx": 10,
          "entities": [
            {
              "entity_id": "T138",
              "entity": "心血管风险",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Cardiovascular risk"
            },
            {
              "entity_id": "T139",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R49",
              "head_entity_id": "T139",
              "tail_entity_id": "T138"
            }
          ],
          "sentence_en": "2.4 Cardiovascular Risk"
        }
      ],
      "paragraph_en": "2.4 Cardiovascular Risk"
    },
    {
      "paragraph_id": "16",
      "paragraph": "美国大学组糖尿病研究项目(UGDP)研究提出，甲苯磺丁脲可能增加T2DM患者心血管死亡风险。UKPDS随机给予新发T2DM患者胰岛素注射或口服降糖药治疗，以了解不同治疗方式对心血管并发症的影响。结果显示，磺脲类药物未增加心血管并发症发生；相反，其后续研究发现磺脲类可减少心血管事件发生。ADVANCE对病程较长，合并心血管高危因素的T2DM患者采用以格列齐特缓释片为基础的降糖治疗，主要微血管事件减少14%。Meta分析结果显示，以氯磺丙脲、格列本脲和格列齐特缓释片为基础的降糖治疗可使T2DM患者非致死性心肌梗死风险降低17%、冠心病风险降低15%。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "美国大学组糖尿病研究项目(UGDP)研究提出，甲苯磺丁脲可能增加T2DM患者心血管死亡风险。UKPDS随机给予新发T2DM患者胰岛素注射或口服降糖药治疗，以了解不同治疗方式对心血管并发症的影响。结果显示，磺脲类药物未增加心血管并发症发生；相反，其后续研究发现磺脲类可减少心血管事件发生。ADVANCE对病程较长，合并心血管高危因素的T2DM患者采用以格列齐特缓释片为基础的降糖治疗，主要微血管事件减少14%。Meta分析结果显示，以氯磺丙脲、格列本脲和格列齐特缓释片为基础的降糖治疗可使T2DM患者非致死性心肌梗死风险降低17%、冠心病风险降低15%。",
          "start_idx": 0,
          "end_idx": 276,
          "entities": [
            {
              "entity_id": "T140",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T141",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 36,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T142",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 57,
              "end_idx": 61,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T143",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 166,
              "end_idx": 170,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T144",
              "entity": "T2DM患者",
              "entity_type": "Disease",
              "start_idx": 243,
              "end_idx": 249,
              "entity_en": "Patients with T2DM"
            },
            {
              "entity_id": "T145",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 253,
              "end_idx": 257,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T146",
              "entity": "冠心病",
              "entity_type": "Disease",
              "start_idx": 265,
              "end_idx": 268,
              "entity_en": "Coronary heart disease"
            },
            {
              "entity_id": "T147",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "T2"
            },
            {
              "entity_id": "T148",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 57,
              "end_idx": 59,
              "entity_en": "T2"
            },
            {
              "entity_id": "T149",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 166,
              "end_idx": 168,
              "entity_en": "T2"
            },
            {
              "entity_id": "T150",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 243,
              "end_idx": 245,
              "entity_en": "T2"
            },
            {
              "entity_id": "T151",
              "entity": "甲苯磺丁脲",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 28,
              "entity_en": "Tolbutamide"
            },
            {
              "entity_id": "T152",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 63,
              "end_idx": 66,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T153",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 102,
              "end_idx": 107,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T154",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 129,
              "end_idx": 132,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T155",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 175,
              "end_idx": 182,
              "entity_en": "Gliclazide extended-release tablets"
            },
            {
              "entity_id": "T156",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 216,
              "end_idx": 220,
              "entity_en": "Chlorpropamide"
            },
            {
              "entity_id": "T157",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 221,
              "end_idx": 225,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T158",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 226,
              "end_idx": 233,
              "entity_en": "Gliclazide extended-release tablets"
            },
            {
              "entity_id": "T159",
              "entity": "心血管并发症",
              "entity_type": "ADE",
              "start_idx": 87,
              "end_idx": 93,
              "entity_en": "Cardiovascular complications"
            },
            {
              "entity_id": "T160",
              "entity": "心血管死亡",
              "entity_type": "ADE",
              "start_idx": 38,
              "end_idx": 43,
              "entity_en": "Cardiovascular death"
            },
            {
              "entity_id": "T161",
              "entity": "心血管并发症",
              "entity_type": "ADE",
              "start_idx": 110,
              "end_idx": 116,
              "entity_en": "Cardiovascular complications"
            },
            {
              "entity_id": "T162",
              "entity": "心血管事件",
              "entity_type": "ADE",
              "start_idx": 135,
              "end_idx": 140,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T163",
              "entity": "微血管事件",
              "entity_type": "ADE",
              "start_idx": 193,
              "end_idx": 198,
              "entity_en": "Microvascular events"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R50",
              "head_entity_id": "T147",
              "tail_entity_id": "T141"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R51",
              "head_entity_id": "T151",
              "tail_entity_id": "T141"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R52",
              "head_entity_id": "T148",
              "tail_entity_id": "T142"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R53",
              "head_entity_id": "T152",
              "tail_entity_id": "T142"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R54",
              "head_entity_id": "T149",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R55",
              "head_entity_id": "T155",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R56",
              "head_entity_id": "T150",
              "tail_entity_id": "T144"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R57",
              "head_entity_id": "T156",
              "tail_entity_id": "T144"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R58",
              "head_entity_id": "T157",
              "tail_entity_id": "T144"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R59",
              "head_entity_id": "T158",
              "tail_entity_id": "T144"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R60",
              "head_entity_id": "T160",
              "tail_entity_id": "T151"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R61",
              "head_entity_id": "T159",
              "tail_entity_id": "T152"
            }
          ],
          "sentence_en": "The University Group Diabetes Research Project (UGDP) in the United States suggested that tolbutamide may increase the risk of cardiovascular death in patients with T2DM. UKPDS randomly gave new-onset T2DM patients insulin injections or oral hypoglycemic drugs to understand the effects of different treatment methods on cardiovascular complications. The results showed that sulfonylureas did not increase the occurrence of cardiovascular complications; on the contrary, its subsequent studies found that sulfonylureas can reduce the occurrence of cardiovascular events. ADVANCE used hypoglycemic treatment based on gliclazide extended-release tablets for T2DM patients with a long course of disease and combined with high cardiovascular risk factors, and major microvascular events were reduced by 14%. Meta-analysis results showed that hypoglycemic treatment based on chlorpropamide, gliclazide extended-release tablets can reduce the risk of non-fatal myocardial infarction in patients with T2DM by 17% and the risk of coronary heart disease by 15%."
        }
      ],
      "paragraph_en": "The University Group Diabetes Research Project (UGDP) in the United States suggested that tolbutamide may increase the risk of cardiovascular death in patients with T2DM. UKPDS randomly gave new-onset T2DM patients insulin injections or oral hypoglycemic drugs to understand the effects of different treatments on cardiovascular complications. The results showed that sulfonylureas did not increase the occurrence of cardiovascular complications; on the contrary, its subsequent studies found that sulfonylureas can reduce the occurrence of cardiovascular events. ADVANCE used hypoglycemic treatment based on gliclazide extended-release tablets for T2DM patients with a long course of disease and combined with high cardiovascular risk factors, and major microvascular events were reduced by 14%. Meta-analysis results showed that hypoglycemic treatment based on chlorpropamide, gliclazide extended-release tablets can reduce the risk of non-fatal myocardial infarction in patients with T2DM by 17% and the risk of coronary heart disease by 15%."
    },
    {
      "paragraph_id": "17",
      "paragraph": "现有的证据表明，胰岛素促泌剂中的磺脲类药物有利于保护T2DM的心血管，没有随机双盲前瞻性长时间研究发现它增加心血管风险。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "现有的证据表明，胰岛素促泌剂中的磺脲类药物有利于保护T2DM的心血管，没有随机双盲前瞻性长时间研究发现它增加心血管风险。",
          "start_idx": 0,
          "end_idx": 60,
          "entities": [
            {
              "entity_id": "T164",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 14,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T165",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 21,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T166",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 30,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T167",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 26,
              "end_idx": 28,
              "entity_en": "T2"
            },
            {
              "entity_id": "T168",
              "entity": "心血管风险",
              "entity_type": "ADE",
              "start_idx": 54,
              "end_idx": 59,
              "entity_en": "Cardiovascular risk"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R62",
              "head_entity_id": "T167",
              "tail_entity_id": "T166"
            }
          ],
          "sentence_en": "Existing evidence suggests that sulfonylureas among insulin secretagogues are beneficial for cardiovascular protection in T2DM, but no randomized, double-blind, prospective, long-term studies have found that they increase cardiovascular risk."
        },
        {
          "sentence_id": "1",
          "sentence": " ",
          "start_idx": 60,
          "end_idx": 61,
          "entities": [],
          "relations": [],
          "sentence_en": " "
        }
      ],
      "paragraph_en": "Existing evidence suggests that sulfonylureas among insulin secretagogues are beneficial for cardiovascular protection in T2DM, but no randomized, double-blind, prospective, long-term studies have found that they increase cardiovascular risk."
    },
    {
      "paragraph_id": "18",
      "paragraph": "2.5 肿瘤风险 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.5 肿瘤风险 ",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [
            {
              "entity_id": "T169",
              "entity": "肿瘤",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "Tumor"
            }
          ],
          "relations": [],
          "sentence_en": "2.5 Tumor Risk"
        }
      ],
      "paragraph_en": "2.5 Tumor Risk"
    },
    {
      "paragraph_id": "19",
      "paragraph": "有研究表明T2DM患者的肿瘤风险增加，甚至某些回顾性的资料分析发现磺脲类药物可能增加肿瘤的风险，但高水平高级别的证据如从UKPDS到近期发表的ADVANCE亚组分析均未发现磺脲类药物增加患者肿瘤风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "有研究表明T2DM患者的肿瘤风险增加，甚至某些回顾性的资料分析发现磺脲类药物可能增加肿瘤的风险，但高水平高级别的证据如从UKPDS到近期发表的ADVANCE亚组分析均未发现磺脲类药物增加患者肿瘤风险。",
          "start_idx": 0,
          "end_idx": 100,
          "entities": [
            {
              "entity_id": "T170",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 9,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T171",
              "entity": "肿瘤",
              "entity_type": "Disease",
              "start_idx": 95,
              "end_idx": 97,
              "entity_en": "Tumor"
            },
            {
              "entity_id": "T172",
              "entity": "肿瘤",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 44,
              "entity_en": "Tumor"
            },
            {
              "entity_id": "T173",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 5,
              "end_idx": 7,
              "entity_en": "T2"
            },
            {
              "entity_id": "T174",
              "entity": "肿瘤",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 14,
              "entity_en": "Tumor"
            },
            {
              "entity_id": "T175",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T176",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 91,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R63",
              "head_entity_id": "T173",
              "tail_entity_id": "T170"
            }
          ],
          "sentence_en": "Some studies have shown that patients with T2DM have an increased risk of cancer, and even some retrospective data analyses have found that sulfonylureas may increase the risk of cancer. However, high-level and high-grade evidence, such as from UKPDS to the recently published ADVANCE subgroup analysis, has not found that sulfonylureas increase patients' risk of cancer."
        }
      ],
      "paragraph_en": "Some studies have shown that patients with T2DM have an increased risk of cancer, and even some retrospective data analyses have found that sulfonylureas may increase the risk of cancer. However, high-level and high-grade evidence, such as from UKPDS to the recently published ADVANCE subgroup analysis, has not found that sulfonylureas increase patients' risk of cancer."
    },
    {
      "paragraph_id": "20",
      "paragraph": "3 胰岛素促泌剂的临床应用 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3 胰岛素促泌剂的临床应用 ",
          "start_idx": 0,
          "end_idx": 14,
          "entities": [
            {
              "entity_id": "T177",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 8,
              "entity_en": "Insulin secretagogues"
            }
          ],
          "relations": [],
          "sentence_en": "3 Clinical application of insulin secretagogues"
        }
      ],
      "paragraph_en": "3 Clinical application of insulin secretagogues"
    },
    {
      "paragraph_id": "21",
      "paragraph": "共识强调胰岛素促泌剂仍是治疗T2DM的一线药，对于有一定β细胞功能、无胰岛素促泌剂应用禁忌的T2DM患者均可考虑选用胰岛素促泌剂。对无超重和肥胖或二甲双胍不耐受者或其他口服降糖药物治疗血糖控制不佳的T2DM患者促泌剂可作为首选或联合药物。应根据患者血糖谱选择不同类型的胰岛素促泌剂：以餐后血糖(PPG)升高为主者宜选择格列奈类及短效磺脲类促泌剂；以空腹血糖(FPG)升高为主PPG和FPG均升高者宜选择依从性好、低血糖风险低的中长效磺脲类促泌剂。若单药治疗血糖控制不达标，应与其他口服降糖药联用，一般联合两种药物，最多可联用3种药物。胰岛素促泌剂可与基础胰岛素合用，但不主张与格列奈类合用。胰岛素促泌剂与其他药物联合使用时应选择作用机制互补的降糖药物，这样既增强药物降糖效果又减少了各自的剂量及体重增加、严重低血糖等不良反应的发生率，同时要评估联合用药的成本-效益因素，充分考虑患者的经济承受能力和用药的依从性，特别是经济欠发达和农村地区患者。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "共识强调胰岛素促泌剂仍是治疗T2DM的一线药，对于有一定β细胞功能、无胰岛素促泌剂应用禁忌的T2DM患者均可考虑选用胰岛素促泌剂。对无超重和肥胖或二甲双胍不耐受者或其他口服降糖药物治疗血糖控制不佳的T2DM患者促泌剂可作为首选或联合药物。应根据患者血糖谱选择不同类型的胰岛素促泌剂：以餐后血糖(PPG)升高为主者宜选择格列奈类及短效磺脲类促泌剂；以空腹血糖(FPG)升高为主PPG和FPG均升高者宜选择依从性好、低血糖风险低的中长效磺脲类促泌剂。",
          "start_idx": 0,
          "end_idx": 223,
          "entities": [
            {
              "entity_id": "T178",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 10,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T179",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 64,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T180",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 73,
              "end_idx": 77,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T181",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 134,
              "end_idx": 140,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T182",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 159,
              "end_idx": 163,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T183",
              "entity": "短效磺脲类促泌剂",
              "entity_type": "Drug",
              "start_idx": 164,
              "end_idx": 172,
              "entity_en": "Short-acting sulfonylurea secretagogues"
            },
            {
              "entity_id": "T184",
              "entity": "中长效磺脲类促泌剂",
              "entity_type": "Drug",
              "start_idx": 213,
              "end_idx": 222,
              "entity_en": "Medium- and long-acting sulfonylurea secretagogues"
            },
            {
              "entity_id": "T189",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 18,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T190",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 50,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T191",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 67,
              "end_idx": 69,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T192",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 70,
              "end_idx": 72,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T193",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 103,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T194",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 14,
              "end_idx": 16,
              "entity_en": "T2"
            },
            {
              "entity_id": "T195",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 46,
              "end_idx": 48,
              "entity_en": "T2"
            },
            {
              "entity_id": "T196",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 99,
              "end_idx": 101,
              "entity_en": "T2"
            },
            {
              "entity_id": "T197",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 41,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T198",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 84,
              "end_idx": 86,
              "entity_en": "oral"
            },
            {
              "entity_id": "T200",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 92,
              "end_idx": 94,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T201",
              "entity": "血糖谱",
              "entity_type": "Test_items",
              "start_idx": 124,
              "end_idx": 127,
              "entity_en": "Blood glucose profile"
            },
            {
              "entity_id": "T202",
              "entity": "餐后血糖(PPG)",
              "entity_type": "Test_items",
              "start_idx": 142,
              "end_idx": 151,
              "entity_en": "Postprandial blood glucose (PPG)"
            },
            {
              "entity_id": "T203",
              "entity": "空腹血糖(FPG)",
              "entity_type": "Test_items",
              "start_idx": 174,
              "end_idx": 183,
              "entity_en": "Fasting blood glucose (FPG)"
            },
            {
              "entity_id": "T204",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 187,
              "end_idx": 190,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T205",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 191,
              "end_idx": 194,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T207",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 94,
              "end_idx": 98,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T208",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 151,
              "end_idx": 153,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T209",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 183,
              "end_idx": 185,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T210",
              "entity": "均升高",
              "entity_type": "Test_Value",
              "start_idx": 194,
              "end_idx": 197,
              "entity_en": "Both increased"
            },
            {
              "entity_id": "T212",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 206,
              "end_idx": 209,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R64",
              "head_entity_id": "T178",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R65",
              "head_entity_id": "T179",
              "tail_entity_id": "T190"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R66",
              "head_entity_id": "T181",
              "tail_entity_id": "T193"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R67",
              "head_entity_id": "T212",
              "tail_entity_id": "T184"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R68",
              "head_entity_id": "T194",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R69",
              "head_entity_id": "T195",
              "tail_entity_id": "T190"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R70",
              "head_entity_id": "T196",
              "tail_entity_id": "T193"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R71",
              "head_entity_id": "T200",
              "tail_entity_id": "T193"
            }
          ],
          "sentence_en": "The consensus emphasizes that insulin secretagogues are still the first-line drugs for the treatment of T2DM. For T2DM patients with certain β-cell function and no contraindications to the use of insulin secretagogues, insulin secretagogues can be considered. For T2DM patients who are not overweight or obese or intolerant to metformin or whose blood sugar is poorly controlled by other oral hypoglycemic drugs, secretagogues can be used as the first choice or combined drugs. Different types of insulin secretagogues should be selected according to the patient's blood sugar profile: those with increased postprandial blood sugar (PPG) should choose meglitinides and short-acting sulfonylurea secretagogues; those with increased fasting blood sugar (FPG) and increased PPG and FPG should choose medium- and long-acting sulfonylurea secretagogues with good compliance and low risk of hypoglycemia."
        },
        {
          "sentence_id": "1",
          "sentence": "若单药治疗血糖控制不达标，应与其他口服降糖药联用，一般联合两种药物，最多可联用3种药物。",
          "start_idx": 223,
          "end_idx": 267,
          "entities": [
            {
              "entity_id": "T199",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "oral"
            },
            {
              "entity_id": "T206",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 5,
              "end_idx": 7,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T211",
              "entity": "控制不达标",
              "entity_type": "Test_Value",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": "Control not up to standard"
            }
          ],
          "relations": [],
          "sentence_en": "If monotherapy fails to achieve target blood sugar control, it should be used in combination with other oral hypoglycemic drugs, generally two drugs, and up to three drugs can be used in combination."
        },
        {
          "sentence_id": "2",
          "sentence": "胰岛素促泌剂可与基础胰岛素合用，但不主张与格列奈类合用。",
          "start_idx": 267,
          "end_idx": 295,
          "entities": [
            {
              "entity_id": "T185",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T186",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T187",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "Meglitinides"
            }
          ],
          "relations": [],
          "sentence_en": "Insulin secretagogues can be used in combination with basal insulin, but are not recommended for use with glinides."
        },
        {
          "sentence_id": "3",
          "sentence": "胰岛素促泌剂与其他药物联合使用时应选择作用机制互补的降糖药物，这样既增强药物降糖效果又减少了各自的剂量及体重增加、严重低血糖等不良反应的发生率，同时要评估联合用药的成本-效益因素，充分考虑患者的经济承受能力和用药的依从性，特别是经济欠发达和农村地区患者。",
          "start_idx": 295,
          "end_idx": 422,
          "entities": [
            {
              "entity_id": "T188",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T213",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 52,
              "end_idx": 56,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T214",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 59,
              "end_idx": 62,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T215",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 57,
              "end_idx": 59,
              "entity_en": "serious"
            }
          ],
          "relations": [],
          "sentence_en": "When insulin secretagogues are used in combination with other drugs, hypoglycemic drugs with complementary mechanisms of action should be selected. This will not only enhance the hypoglycemic effect of the drugs, but also reduce the respective dosages and the incidence of adverse reactions such as weight gain and severe hypoglycemia. At the same time, the cost-effectiveness factors of the combined drug use should be evaluated, and the patient's economic affordability and medication compliance should be fully considered, especially for patients in economically underdeveloped and rural areas."
        },
        {
          "sentence_id": "4",
          "sentence": " ",
          "start_idx": 422,
          "end_idx": 423,
          "entities": [],
          "relations": [],
          "sentence_en": " "
        }
      ],
      "paragraph_en": "The consensus emphasizes that insulin secretagogues are still the first-line drugs for the treatment of T2DM. For T2DM patients with certain β-cell function and no contraindications to the use of insulin secretagogues, insulin secretagogues can be considered. For T2DM patients who are not overweight or obese or intolerant to metformin or whose blood sugar control is poor with other oral hypoglycemic drugs, secretagogues can be used as the first choice or combined drugs. Different types of insulin secretagogues should be selected according to the patient's blood sugar profile: those with increased postprandial blood sugar (PPG) should choose glinides and short-acting sulfonylurea secretagogues; those with increased fasting blood sugar (FPG) and increased PPG and FPG should choose medium- and long-acting sulfonylurea secretagogues with good compliance and low risk of hypoglycemia. If monotherapy fails to achieve blood sugar control, it should be used in combination with other oral hypoglycemic drugs, generally two drugs, and up to three drugs can be used in combination. Insulin secretagogues can be used in combination with basal insulin, but it is not recommended to be used in combination with glinides. When insulin secretagogues are used in combination with other drugs, glucose-lowering drugs with complementary mechanisms of action should be selected. This will not only enhance the glucose-lowering effect of the drugs, but also reduce their respective dosages and the incidence of adverse reactions such as weight gain and severe hypoglycemia. At the same time, the cost-effectiveness factors of the combined drug use should be evaluated, and the patient's economic affordability and medication compliance should be fully considered, especially for patients in economically underdeveloped and rural areas."
    },
    {
      "paragraph_id": "22",
      "paragraph": "胰岛素促泌剂的降糖作用在常规剂量内呈剂量依赖性，可平均将糖化血红蛋白(HbA1c)水平降低2%左右，且患者的基线HbA1c水平越高，服用胰鸟素促泌剂治疗后HbA1c的降幅越大。剂量应从小量开始，以减少低血糖发生。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "胰岛素促泌剂的降糖作用在常规剂量内呈剂量依赖性，可平均将糖化血红蛋白(HbA1c)水平降低2%左右，且患者的基线HbA1c水平越高，服用胰鸟素促泌剂治疗后HbA1c的降幅越大。",
          "start_idx": 0,
          "end_idx": 88,
          "entities": [
            {
              "entity_id": "T216",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T217",
              "entity": "胰鸟素促泌剂",
              "entity_type": "Drug",
              "start_idx": 68,
              "end_idx": 74,
              "entity_en": "Pancreatic secretagogue"
            },
            {
              "entity_id": "T218",
              "entity": "糖化血红蛋白(HbA1c)",
              "entity_type": "Test_items",
              "start_idx": 28,
              "end_idx": 41,
              "entity_en": "Glycated hemoglobin (HbA1c)"
            },
            {
              "entity_id": "T219",
              "entity": "基线HbA1c",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 61,
              "entity_en": "Baseline HbA1c"
            },
            {
              "entity_id": "T220",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 77,
              "end_idx": 82,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T221",
              "entity": "降低2%左右",
              "entity_type": "Test_Value",
              "start_idx": 43,
              "end_idx": 49,
              "entity_en": "Reduce by about 2%"
            },
            {
              "entity_id": "T222",
              "entity": "高",
              "entity_type": "Test_Value",
              "start_idx": 64,
              "end_idx": 65,
              "entity_en": "high"
            },
            {
              "entity_id": "T223",
              "entity": "降幅越大",
              "entity_type": "Test_Value",
              "start_idx": 83,
              "end_idx": 87,
              "entity_en": "The bigger the drop"
            }
          ],
          "relations": [],
          "sentence_en": "The glucose-lowering effect of insulin secretagogues is dose-dependent within conventional doses, and can reduce glycated hemoglobin (HbA1c) levels by an average of about 2%. The higher the patient's baseline HbA1c level, the greater the reduction in HbA1c after taking insulin secretagogues."
        },
        {
          "sentence_id": "1",
          "sentence": "剂量应从小量开始，以减少低血糖发生。",
          "start_idx": 88,
          "end_idx": 106,
          "entities": [
            {
              "entity_id": "T224",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [],
          "sentence_en": "The dose should be started small to reduce the risk of hypoglycemia."
        },
        {
          "sentence_id": "2",
          "sentence": " ",
          "start_idx": 106,
          "end_idx": 107,
          "entities": [],
          "relations": [],
          "sentence_en": " "
        }
      ],
      "paragraph_en": "The glucose-lowering effect of insulin secretagogues is dose-dependent within conventional doses, and can reduce the glycated hemoglobin (HbA1c) level by about 2% on average. The higher the patient's baseline HbA1c level, the greater the reduction in HbA1c after taking insulin secretagogues. The dose should start with a small amount to reduce the occurrence of hypoglycemia."
    },
    {
      "paragraph_id": "23",
      "paragraph": "中或重度肝肾功能不全者不宜使用胰岛素促泌剂。轻中度肾功能不全者若不用胰岛素，需要用胰岛素促泌剂时可考虑瑞格列奈和格列喹酮。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "中或重度肝肾功能不全者不宜使用胰岛素促泌剂。轻中度肾功能不全者若不用胰岛素，需要用胰岛素促泌剂时可考虑瑞格列奈和格列喹酮。",
          "start_idx": 0,
          "end_idx": 61,
          "entities": [
            {
              "entity_id": "T225",
              "entity": "肝肾功能不全",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 10,
              "entity_en": "Liver and kidney dysfunction"
            },
            {
              "entity_id": "T226",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 5,
              "entity_en": "liver"
            },
            {
              "entity_id": "T227",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 5,
              "end_idx": 6,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T228",
              "entity": "中或重度",
              "entity_type": "Level",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Moderate or severe"
            },
            {
              "entity_id": "T229",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 21,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T230",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 30,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T231",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 25,
              "end_idx": 26,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T232",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T233",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 41,
              "end_idx": 47,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T234",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 55,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T235",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 56,
              "end_idx": 60,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T236",
              "entity": "轻中度",
              "entity_type": "Level",
              "start_idx": 22,
              "end_idx": 25,
              "entity_en": "Mild to moderate"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R72",
              "head_entity_id": "T226",
              "tail_entity_id": "T225"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R73",
              "head_entity_id": "T227",
              "tail_entity_id": "T225"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R74",
              "head_entity_id": "T231",
              "tail_entity_id": "T230"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R75",
              "head_entity_id": "T233",
              "tail_entity_id": "T230"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R76",
              "head_entity_id": "T234",
              "tail_entity_id": "T230"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R77",
              "head_entity_id": "T235",
              "tail_entity_id": "T230"
            }
          ],
          "sentence_en": "Patients with moderate or severe hepatic and renal insufficiency should not use insulin secretagogues. Patients with mild to moderate renal insufficiency who do not use insulin but need to use insulin secretagogues may consider repaglinide and gliclazide."
        }
      ],
      "paragraph_en": "Patients with moderate or severe hepatic and renal insufficiency should not use insulin secretagogues. Patients with mild to moderate renal insufficiency who do not use insulin but need to use insulin secretagogues may consider repaglinide and gliclazide."
    },
    {
      "paragraph_id": "24",
      "paragraph": "总之，胰岛素促泌剂符合中国2型糖尿病的特点，是多数权威指南推荐的治疗2型糖尿病的一线药物。磺脲类药物应用时间长、降糖效果强、安全性高、价格低廉，早期使用可减少大血管、微血管、并发症和全因死亡的发生。格列奈类有效降低餐后血糖，在中国也广泛使用。临床医生应以循证医学研究的证据来科学评价胰岛素促泌剂，同时应充分了解各种药物的特点，结合患者的血糖谱、年龄、病程、肝肾功能、胰岛功能、依从性、经济条件等情况综合考虑，制定个体化的用药方案，使患者血糖安全达标的同时减少不良反应的发生，延缓疾病进程，减少并发症，提高患者的生活质量。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "总之，胰岛素促泌剂符合中国2型糖尿病的特点，是多数权威指南推荐的治疗2型糖尿病的一线药物。",
          "start_idx": 0,
          "end_idx": 45,
          "entities": [
            {
              "entity_id": "T237",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 9,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T241",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 18,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T242",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 39,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T243",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T244",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 34,
              "end_idx": 36,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R78",
              "head_entity_id": "T243",
              "tail_entity_id": "T241"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R79",
              "head_entity_id": "T244",
              "tail_entity_id": "T242"
            }
          ],
          "sentence_en": "In short, insulin secretagogues are in line with the characteristics of type 2 diabetes in China and are the first-line drugs recommended by most authoritative guidelines for the treatment of type 2 diabetes."
        },
        {
          "sentence_id": "1",
          "sentence": "磺脲类药物应用时间长、降糖效果强、安全性高、价格低廉，早期使用可减少大血管、微血管、并发症和全因死亡的发生。",
          "start_idx": 45,
          "end_idx": 99,
          "entities": [
            {
              "entity_id": "T238",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "Sulfonylurea drugs have a long application time, strong hypoglycemic effect, high safety and low price. Early use can reduce the occurrence of large blood vessels, microvessels, complications and all-cause mortality."
        },
        {
          "sentence_id": "2",
          "sentence": "格列奈类有效降低餐后血糖，在中国也广泛使用。",
          "start_idx": 99,
          "end_idx": 121,
          "entities": [
            {
              "entity_id": "T239",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T245",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "Postprandial blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "Meglitinides are effective in lowering postprandial blood sugar and are widely used in China."
        },
        {
          "sentence_id": "3",
          "sentence": "临床医生应以循证医学研究的证据来科学评价胰岛素促泌剂，同时应充分了解各种药物的特点，结合患者的血糖谱、年龄、病程、肝肾功能、胰岛功能、依从性、经济条件等情况综合考虑，制定个体化的用药方案，使患者血糖安全达标的同时减少不良反应的发生，延缓疾病进程，减少并发症，提高患者的生活质量。",
          "start_idx": 121,
          "end_idx": 260,
          "entities": [
            {
              "entity_id": "T240",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 26,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T246",
              "entity": "血糖谱",
              "entity_type": "Test_items",
              "start_idx": 47,
              "end_idx": 50,
              "entity_en": "Blood glucose profile"
            },
            {
              "entity_id": "T247",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 97,
              "end_idx": 99,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T248",
              "entity": "安全达标",
              "entity_type": "Test_Value",
              "start_idx": 99,
              "end_idx": 103,
              "entity_en": "Safety compliance"
            }
          ],
          "relations": [],
          "sentence_en": "Clinicians should scientifically evaluate insulin secretagogues based on evidence from evidence-based medical research. At the same time, they should fully understand the characteristics of various drugs, take into account the patient's blood sugar profile, age, course of disease, liver and kidney function, pancreatic function, compliance, economic conditions, etc., and develop an individualized medication plan to ensure that the patient's blood sugar safely reaches the standard while reducing the occurrence of adverse reactions, delaying the progression of the disease, reducing complications, and improving the patient's quality of life."
        },
        {
          "sentence_id": "4",
          "sentence": " ",
          "start_idx": 260,
          "end_idx": 261,
          "entities": [],
          "relations": [],
          "sentence_en": " "
        }
      ],
      "paragraph_en": "In short, insulin secretagogues meet the characteristics of type 2 diabetes in China and are the first-line drugs recommended by most authoritative guidelines for the treatment of type 2 diabetes. Sulfonylureas have a long application time, strong hypoglycemic effect, high safety, and low price. Early use can reduce the occurrence of large blood vessels, microvascular diseases, complications, and all-cause mortality. Glinides effectively reduce postprandial blood sugar and are also widely used in China. Clinicians should scientifically evaluate insulin secretagogues based on evidence from evidence-based medical research. At the same time, they should fully understand the characteristics of various drugs, and formulate individualized medication plans based on the patient's blood sugar profile, age, course of disease, liver and kidney function, pancreatic islet function, compliance, economic conditions, etc., so as to ensure that the patient's blood sugar safely reaches the standard while reducing the occurrence of adverse reactions, delaying the progression of the disease, reducing complications, and improving the patient's quality of life."
    }
  ]
}